Brandon Michael Huffman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 8 | 2024 | 5368 | 1.060 |
Why?
|
Carcinoma, Pancreatic Ductal | 4 | 2024 | 1727 | 1.040 |
Why?
|
Anus Neoplasms | 2 | 2024 | 329 | 0.860 |
Why?
|
Adenocarcinoma | 6 | 2024 | 6346 | 0.840 |
Why?
|
Esophageal Neoplasms | 3 | 2024 | 1654 | 0.630 |
Why?
|
Stomach Neoplasms | 3 | 2024 | 1459 | 0.630 |
Why?
|
Intestinal Neoplasms | 1 | 2019 | 312 | 0.540 |
Why?
|
Carcinoma, Papillary | 2 | 2019 | 785 | 0.540 |
Why?
|
Pancytopenia | 1 | 2017 | 102 | 0.530 |
Why?
|
Blood Cell Count | 1 | 2017 | 397 | 0.530 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11742 | 0.520 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1613 | 0.490 |
Why?
|
Pancreas | 2 | 2019 | 1691 | 0.480 |
Why?
|
Education, Medical | 2 | 2023 | 1725 | 0.460 |
Why?
|
Learning | 1 | 2023 | 1740 | 0.450 |
Why?
|
Intestine, Small | 1 | 2019 | 1206 | 0.420 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2024 | 4026 | 0.380 |
Why?
|
Deoxycytidine | 3 | 2024 | 877 | 0.380 |
Why?
|
Leucovorin | 2 | 2024 | 643 | 0.350 |
Why?
|
Paclitaxel | 3 | 2024 | 1732 | 0.300 |
Why?
|
Fluorouracil | 2 | 2024 | 1641 | 0.280 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9177 | 0.260 |
Why?
|
Immunotherapy | 2 | 2024 | 4652 | 0.220 |
Why?
|
Epithelial Cells | 1 | 2015 | 3673 | 0.210 |
Why?
|
Mucin 5AC | 1 | 2023 | 96 | 0.210 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 155 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 3 | 2024 | 6484 | 0.180 |
Why?
|
Socialization | 1 | 2020 | 87 | 0.180 |
Why?
|
Exercise | 1 | 2017 | 5890 | 0.180 |
Why?
|
Internship and Residency | 1 | 2020 | 5880 | 0.170 |
Why?
|
Melanoma | 1 | 2018 | 5709 | 0.170 |
Why?
|
Competency-Based Education | 1 | 2020 | 222 | 0.160 |
Why?
|
Interleukin-1beta | 1 | 2024 | 999 | 0.160 |
Why?
|
Organoplatinum Compounds | 1 | 2019 | 407 | 0.150 |
Why?
|
Pancreas Transplantation | 1 | 2018 | 197 | 0.140 |
Why?
|
Prognosis | 5 | 2024 | 29625 | 0.140 |
Why?
|
Lymphocyte Count | 1 | 2019 | 778 | 0.140 |
Why?
|
Pancreatic Diseases | 1 | 2019 | 343 | 0.140 |
Why?
|
Feedback | 1 | 2020 | 791 | 0.140 |
Why?
|
Iliac Artery | 1 | 2018 | 343 | 0.140 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 711 | 0.140 |
Why?
|
Neoadjuvant Therapy | 2 | 2024 | 2827 | 0.130 |
Why?
|
Aneurysm, False | 1 | 2018 | 255 | 0.130 |
Why?
|
DNA Copy Number Variations | 1 | 2024 | 2020 | 0.120 |
Why?
|
Humans | 22 | 2024 | 761504 | 0.120 |
Why?
|
Retrospective Studies | 6 | 2024 | 80636 | 0.120 |
Why?
|
Histocytochemistry | 1 | 2015 | 698 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2917 | 0.110 |
Why?
|
Aged | 9 | 2024 | 169289 | 0.100 |
Why?
|
Age Factors | 2 | 2019 | 18395 | 0.100 |
Why?
|
Cytosol | 1 | 2015 | 888 | 0.100 |
Why?
|
Mucins | 1 | 2015 | 568 | 0.100 |
Why?
|
Aged, 80 and over | 4 | 2024 | 58976 | 0.090 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2018 | 1116 | 0.090 |
Why?
|
Middle Aged | 10 | 2024 | 220895 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3514 | 0.090 |
Why?
|
DNA | 1 | 2024 | 7212 | 0.090 |
Why?
|
Monocytes | 1 | 2019 | 2570 | 0.080 |
Why?
|
Qualitative Research | 1 | 2020 | 3023 | 0.080 |
Why?
|
Male | 12 | 2024 | 360804 | 0.080 |
Why?
|
Observer Variation | 1 | 2015 | 2606 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9280 | 0.080 |
Why?
|
Adult | 7 | 2024 | 221177 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2020 | 2373 | 0.080 |
Why?
|
Disease Management | 1 | 2018 | 2508 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5671 | 0.070 |
Why?
|
ROC Curve | 1 | 2015 | 3579 | 0.070 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39106 | 0.070 |
Why?
|
Bone Marrow | 1 | 2017 | 2911 | 0.070 |
Why?
|
Female | 10 | 2024 | 392644 | 0.070 |
Why?
|
Communication | 1 | 2020 | 3873 | 0.070 |
Why?
|
Cell Nucleus | 1 | 2015 | 2909 | 0.070 |
Why?
|
Neoplasms | 1 | 2015 | 22170 | 0.070 |
Why?
|
Biopsy | 1 | 2017 | 6766 | 0.060 |
Why?
|
Sex Factors | 1 | 2018 | 10552 | 0.060 |
Why?
|
Neoplasm Staging | 1 | 2019 | 11121 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2024 | 6935 | 0.060 |
Why?
|
Survival Rate | 1 | 2018 | 12725 | 0.060 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12463 | 0.060 |
Why?
|
Young Adult | 3 | 2019 | 59243 | 0.050 |
Why?
|
Cohort Studies | 2 | 2023 | 41487 | 0.050 |
Why?
|
Esophagogastric Junction | 1 | 2024 | 347 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4591 | 0.050 |
Why?
|
Human papillomavirus 16 | 1 | 2024 | 267 | 0.050 |
Why?
|
Albumins | 1 | 2024 | 575 | 0.050 |
Why?
|
Disease Progression | 1 | 2018 | 13506 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3877 | 0.050 |
Why?
|
Adolescent | 3 | 2019 | 88319 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13639 | 0.050 |
Why?
|
North America | 1 | 2024 | 1276 | 0.040 |
Why?
|
Social Identification | 1 | 2020 | 108 | 0.040 |
Why?
|
Gene Amplification | 1 | 2024 | 1089 | 0.040 |
Why?
|
Prospective Studies | 1 | 2024 | 54425 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2023 | 1745 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2202 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2015 | 20098 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1745 | 0.030 |
Why?
|
Mutation | 3 | 2024 | 30052 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2018 | 983 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2024 | 4915 | 0.030 |
Why?
|
Risk Assessment | 1 | 2015 | 23995 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2024 | 2557 | 0.030 |
Why?
|
DNA Repair | 1 | 2021 | 2045 | 0.020 |
Why?
|
Risk Factors | 1 | 2019 | 74206 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3639 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4580 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2024 | 7594 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5305 | 0.020 |
Why?
|
Genomics | 1 | 2024 | 5821 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9420 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2024 | 8547 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2024 | 64680 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10090 | 0.020 |
Why?
|
Clinical Competence | 1 | 2020 | 4792 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2018 | 3415 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81525 | 0.010 |
Why?
|
Animals | 1 | 2024 | 168459 | 0.010 |
Why?
|